Pfizer Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Friday 13th, February 2026
External Deadline: Wednesday 18th, February 2026
Description
Pfizer and ALK Positive are collaborating to offer a new grant opportunity seeking proposals for independent medical education initiatives. Through this effort, our goals are to help individuals diagnosed with advanced ALK+ non-small cell lung cancer (NSCLC) by supporting projects that focus on enhancing the knowledge of patients and care partners.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer and ALK Positive must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: December 3, 2025
Geographic Scope: North America, South America, Europe and Australia
Clinical Area: Oncology-Lung cancer: advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
Link to full RFP: Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)
Application Due Date: February 18, 2026
Specific Area of Interest: Projects that will be considered for this RFP will focus on enhancing the knowledge of patients and care partners in the following areas:
- – Preparation of patients and care partners for ALK inhibitor therapy, side-effect management, including what to expect during treatment and how to engage with their healthcare team.
- – Development of material pertaining to prompt side-effect (adverse events) recognition, including lifestyle recommendations, to preserve / support quality of life.
– Development of tools that emphasize patient preferences, facilitate preference-informed decision-making, and ensure inclusivity and accessibility for example: providing multilingual resources.
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Amanda Stein (amanda.j.stein@pfizer.com).